#Canada #Toronto #Xtalks #Sciensus #Early Evidence

Explore the Impact of Early Real-World Evidence in Biotech

In the ever-evolving landscape of biotechnology, the role of early real-world evidence (RWE) generation cannot be overlooked. As the industry faces increasing demands for transparency and efficiency, understanding how to collect and utilize real-world evidence is crucial for success.

As part of a free upcoming webinar hosted by Xtalks, industry experts will take a deep dive into the strategic significance of RWE in driving commercial success in biotech development. This event aims to equip attendees with knowledge about essential data requirements, optimal timing for data collection, and effective strategies for integrating evidence generation throughout the product lifecycle.

Understanding Real-World Evidence

Real-world evidence refers to the clinical evidence derived from the analysis of data collected from various sources outside conventional clinical trials. This evidence is integral for assessing different aspects of a product’s performance in the real world, including safety, efficacy, and cost-effectiveness. The use of RWE can significantly impact key areas such as regulatory approvals and reimbursement strategies, ultimately influencing a product's market access and sustainability.

However, many biotech companies often delay the design and execution of their RWE strategies, leading to costly repercussions. In this webinar, experts will outline the severe implications of such delays, including forfeiting market opportunities, impacting pricing strategies, and undermining health technology assessment (HTA) outcomes. Attendees will learn that aligning evidence generation plans with business goals is essential for mitigating risks and maximizing the value of their products.

Key Insights from the Webinar

The featured speakers for the event, Noolie Gregory, Head of Evidence Generation, and Andrew Cummins, Vice President of Business Development from Sciensus, will share insights based on real-world case studies and current market trends. The presentations will breakdown the various stages of product development and clarify what constitutes appropriate ‘fit-for-purpose’ evidence at each stage.

Through concrete examples of successful early evidence strategies, participants will gain valuable insights on:

• - Integrating Evidence Generation into Business Development: Understanding how early RWE efforts can align with regulatory and reimbursement objectives.
• - Reducing Market Access Uncertainties: Strategies to address potential obstacles and enhance a product’s value proposition.
• - Real-World Case Studies: Analyze how leading biotech companies have successfully navigated the RWE landscape to achieve favorable market outcomes.

Dates and Registration

The live webinar will take place on Monday, November 24, 2025, at 11 am EST (5 pm CET/EU-Central). This is an excellent opportunity for professionals involved in biotech product development to update their knowledge and refine their strategies regarding evidence generation.

To register for this insightful event, visit the Xtalks website and secure your spot. Don’t miss out on the chance to discover how implementing a proactive real-world evidence strategy can reshape the future of your biotech ventures.

Sciensus, a pioneer in integrated commercial services with over three decades of experience, is committed to ensuring that the right medicines reach the right patients across Europe. The upcoming session promises to be a pivotal moment for any professional looking to enhance their understanding of RWE’s impact on commercial success in the biotech sector.

Conclusion

As the biotech industry continues to grow and face new challenges, leveraging early real-world evidence generation will be a key determinant of future commercial success. Join us in this enlightening webinar to learn how to navigate this essential aspect of biotech development effectively.